Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01972919 · ClinicalTrials.gov registry record · Phase 2

MR Guided Phase II Radiotherapy Dose Escalation in Unresectable Non-Metastatic Pancreatic Cancer

A Phase 2 study of Unresectable Pancreatic Cancer, sponsored by Medical College of Wisconsin.

Active
Registry status
Phase 2
Development phase
23
Enrollment target
1
Study location

NCT01972919 is a Phase 2 study of Unresectable Pancreatic Cancer that is active but no longer recruiting, run by Medical College of Wisconsin. The registered enrollment target is 23 participants, below the 88-participant average among 4 other Unresectable Pancreatic Cancer trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01972919, a Phase 2 study of Unresectable Pancreatic Cancer, is active but no longer recruiting, sponsored by Medical College of Wisconsin.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
23 participants
Enrollment target
1
Study location

Study Summary

This research study is for people who have pancreas cancer for which surgery is not recommended. Potential patients must have already received several months of chemotherapy before they are eligible for this study and there will not have been any detectable spread of their tumor on imaging studies following this chemotherapy course.

Interventions

  • RADIATION Radiation Therapy
  • DRUG Concurrent chemotherapy (Gemcitabine, Capecitabine)

Study Locations (1)

Wisconsin

  • Froedtert Hospital - Milwaukee

Trial Details

FieldValue
Enrollment Target 23 participants
Start Date 2015-12-10
Est. Completion 2026-03
Phase Phase 2

Sponsor

Medical College of Wisconsin

447 total trials

What the Registry Record Tells You About NCT01972919

The ClinicalTrials.gov registry entry for NCT01972919 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 88-participant average among 4 other Unresectable Pancreatic Cancer trials with a reported enrollment target (74% lower). The listed sponsor is Medical College of Wisconsin, which has 447 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Unresectable Pancreatic Cancer appearing as the primary indexed condition, and to 2 interventions - of which Radiation Therapy is the first listed.

NCT01972919 reports 1 study location spanning 1 distinct geographic area - top geographies include Wisconsin.

Frequently Asked Questions

What is clinical trial NCT01972919 about?

NCT01972919 is a clinical study titled "MR Guided Phase II Radiotherapy Dose Escalation in Unresectable Non-Metastatic Pancreatic Cancer". This research study is for people who have pancreas cancer for which surgery is not recommended. Potential patients must have already received several months of chemotherapy before they are eligible for this study and there will not have been any detectable spread of their tumor on imaging studies f...

What is the current status of trial NCT01972919?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2015-12-10. Estimated completion is 2026-03.

What conditions does trial NCT01972919 study?

This clinical trial studies the following conditions: Unresectable Pancreatic Cancer.

What interventions are being tested in trial NCT01972919?

The interventions under investigation include: Radiation Therapy (RADIATION), Concurrent chemotherapy (Gemcitabine, Capecitabine) (DRUG).

Who is sponsoring clinical trial NCT01972919?

This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01972919 being conducted?

This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Unresectable Pancreatic Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.